Vitae Pharmaceuticals, Inc.

Intrexon Corporation

Boehringer Ingelheim International Gmbh

Vitae Pharmaceuticals, Inc./boehringer-ingelheim

Colin M Tice

Suresh B Singh

David A Claremon

Linghang Zhuang

Wei Zhao

Yuanjie Ye

Lawrence Wayne Dillard

Zhenrong Xu

Yi Fan

Katerina Leftheris

Jing Yuan

Stephen D Lotesta

Salvacion Cacatian

Chengguo Dong

Yajun Zheng

Robert Eugene Hormann

Lanqi Jia

Robert Simpson

Andrew Marcus

Orestes Chortyk

Gerard McGeehan

John J Baldwin

Alexey V Ishchenko

Glenn Richard Carlson

Patrick Flaherty

Thomas R Opie

David W Potter

Andrew Meyer

Wei He

Frank Himmelsbach

Zhijie Liu

Howard Smith

Thomas Meteyer

Matthias Eckhardt

Enrique Luis Michelotti

Jean-Pierre Wery

Gerard M Mcgeehan

Patrick T Flaherty

Linghang Zhung

Robert D Simpson

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR&#x3b3;. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Dihydropyrrolopyridine inhibitors of ROR-gamma

Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR&#x3b3;. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders. 

Modulators of ROR-gamma

Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders. 

Benzimidazole derivatives as modulators of ROR-gamma

Provided are indole, benzoimidazole, pyrrolopyridine, and imidazopyridine derivatives and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR&#x3b3;. Such derivatives include e.g., those having the Formula II:  as well as pharmaceutically acceptable salts thereof. The disclosed derivatives may be used for treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Substituted benzoimidazoles as modulators of ROR-&#x3b3;

Provided are novel compounds of Formula (I):  pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Substituted indoles as modulators of ROR-gamma

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver X receptor modulators, and which are useful in the treatment of diseases and disorders associated with the liver X receptor. Also provided are the compounds of Formula (I) and pharmaceutical compositions thereof for treating atherosclerosis, cardiovascular disease, Alzheimer's disease, dermatitis, dyslipidemia, cancer and other diseases or disorders. 

Piperazine derivatives as liver X receptor modulators

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Dihydropyrrolopyridine inhibitors of ROR&#x3b3;

Thiazolopyrrolidine inhibitors of ROR- &#x3b3;

Isoindoline inhibitors of ROR-gamma

Provided herein are novel compounds and pharmaceutically acceptable salts thereof that are liver X receptor modulators. Also provided are compositions comprising compounds of the invention and a carrier. Additionally, use of the compounds herein and methods for treating a disease or disorder associated with the liver X receptor are further described.

Liver X receptor modulators

This invention relates to a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. The ligands comprise a class of ketones.

Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex

Growing community of inventors

Ambler, PA, United States of America

Colin M Tice